Los Angeles Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Los Angeles Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$521K	Sell	23,850 -4,688	-16%	-$97.5K	﹤0.01%	906
2026 Q1	$667K	Sell	28,538 -36,742	-56%	-$798K	﹤0.01%	785
2025 Q4	$874K	Buy	65,280 +10,066	+18%	+$176K	﹤0.01%	683
2025 Q3	$849K	Buy	+55,214	New	+$723K	﹤0.01%	748
2022 Q2	–	Sell	-22,844	Closed	-$397K	–	1453
2022 Q1	$397K	Hold	22,844	–	–	﹤0.01%	1133
2021 Q4	$500K	Hold	22,844	–	–	﹤0.01%	1010
2021 Q3	$437K	Buy	22,844 +5,300	+30%	+$88.3K	﹤0.01%	1121
2021 Q2	$301K	Buy	+17,544	New	+$321K	﹤0.01%	1384
2020 Q4	–	Sell	-15,392	Closed	-$227K	–	1546
2020 Q3	$227K	Sell	15,392 -33,628	-69%	-$513K	﹤0.01%	1361
2020 Q2	$726K	Buy	49,020 +19,300	+65%	+$294K	﹤0.01%	970
2020 Q1	$326K	Buy	+29,720	New	+$279K	﹤0.01%	1027
2018 Q3	–	Sell	-70,140	Closed	-$492K	–	1483
2018 Q2	$492K	Buy	70,140 +56,988	+433%	+$559K	﹤0.01%	1139
2018 Q1	$187K	Sell	13,152 -38,287	-74%	-$406K	﹤0.01%	1273
2017 Q4	$451K	Buy	51,439 +37,549	+270%	+$372K	﹤0.01%	1079
2017 Q3	$163K	Buy	+13,890	New	+$170K	﹤0.01%	1264

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Los Angeles Capital Management's SNDX Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Syndax Pharmaceuticals (SNDX) stake by 16% in Q2 2026, selling an estimated $97.5K and leaving 23,850 shares worth $521K. The position accounts for ﹤0.01% of the portfolio, ranked #906.

Los Angeles Capital Management first reported a position in SNDX in Q3 2017 and has held it in 15 quarters since. The position peaked at $874K in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Los Angeles Capital Management held 23,850 shares of Syndax Pharmaceuticals worth $521K as of Q2 2026.
Los Angeles Capital Management sold 4,688 Syndax Pharmaceuticals shares in Q2 2026, an estimated $97.5K.
Syndax Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #906 holding.
Los Angeles Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2017 and has held it in 15 quarters since.
Los Angeles Capital Management's Syndax Pharmaceuticals position peaked at $874K in Q4 2025.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.